Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”

Article information

Clin Mol Hepatol. 2023;29(1):163-164

Publication date (electronic) : 2022 October 27

doi : https://doi.org/10.3350/cmh.2022.0326

Yuanbin Liu, Mingkai Chen

Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China

Corresponding author : Mingkai Chen Department of Gastroenterology, Renmin Hospital of Wuhan University, No. 99 Zhang Zhidong Road, Wuhan, Hubei 430060, China Tel: +86-13720330580, Fax: +86-27-88042292, E-mail: chenmingkai@whu.edu.cn

Editor: Seung Up Kim, Yonsei University College of Medicine, Korea

Received 2022 October 21; Revised 2022 October 24; Accepted 2022 October 25.

Dear Editor,

We read with great interest the recently published article by Lee and colleagues [1], which demonstrated that auranofin, a gold compound, can inhibit the progression of nonalcoholic steatohepatitis (NASH) in both in vivo and in vitro models. This study revealed that auranofin reduced fibrosis and the expression of nuclear factor kappa B (NF-κB) and inhibitor of NF-κB alpha in LX-2 cells; while in HepG2 cells, auranofin increased nuclear erythroid 2-related factor 2 expression and significantly reduced inflammation and adipogenesis [1]. Furthermore, auranofin has also been shown to impede disease progression in fibrosis and NASH models [1]. This study is of great importance as there is currently no effective pharmacological treatment for nonalcoholic fatty liver disease (NAFLD), and auranofin may have potential for repurposing in NAFLD as an agent historically used in rheumatoid arthritis. However, as a reintroduced compound that may have beneficial effects in NAFLD, we would like to provide additional insights regarding the role of auranofin in NAFLD.

Hepatic inflammatory infiltration is a significant feature in NAFLD. Hwangbo et al. [2] suggested that auranofin could reduce the expression of inflammatory markers, including the NOD-like receptor family pyrin domain containing 3, in NAFLD and inhibit hepatic steatosis in both in vivo and in vitro models. These results confirmed that auranofin also has anti-inflammatory properties in NAFLD. A recent study combining in silico screen, in vivo and in vitro models demonstrated the antidiabetic effects of auranofin at the 1 mg/kg dose in obese mice fed with high-fat diet [3]. Auranofin was proved to accumulate in the white adipose tissue of obese mice, improve insulin sensitivity, exert anti-inflammatory effects, and abolish fatty liver disease [3]. Notably, auranofin reduced serum leptin levels, and intact leptin signaling was required for auranofin to exhibit insulin sensitizing effects [3]. The presence of hyperleptinemia and leptin resistance in obese patients suggest that partial reduction of leptin by auranofin may be used as a strategy against obesity and NAFLD. The interferon regulatory factor 3 (IRF3) signaling pathway promotes hepatocyte inflammation and apoptosis in NAFLD [4]. Auranofin inhibited fatty acid-induced hepatocyte apoptosis in an in vitro model by inducing cellular autophagy and thereby degrading IRF3 [5].

Auranofin is also known as a pan-inhibitor of thioredoxin reductase (TrxR) [6]. By inhibiting TrxR, auranofin induced apoptosis in hepatocellular carcinoma (HCC) cells and inhibited tumor growth, together with improved resistance to sorafenib [7]. Ferroptosis is a recently proposed iron-dependent form of cell death characterized by lipid peroxidation and accumulation of reactive oxygen species [8]. High-dose auranofin has been shown to induce ferroptosis by inhibiting TrxR [6]. The role of ferroptosis in NAFLD has been recently studied, and the effects are varied at different stages. Ferroptosis promotes the progression of hepatic steatosis, NASH, and associated fibrosis, while inhibiting the development of cirrhosis and HCC [9]. Auranofin and buthionine sulfoxime co-treatment induced ferroptosis in HCC cell lines [10]. These findings indicate that auranofin could inhibit cell proliferation by regulating cell death in HCC. However, there has been no relevant study suggesting the effects of TrxR inhibition by auranofin in hepatic steatosis and NASH progression. Furthermore, given that ferroptosis may have opposite effects on different stages of NAFLD, future studies are needed to explore the effect of auranofin on ferroptosis in NASH. Whether there is an optimal time point for modulating ferroptosis still requires further exploration, as NASH will eventually progress to HCC.

Overall, the present study demonstrated that auranofin can inhibit NASH progression under experimental conditions, suggesting that it could be a promising repurposed anti-NAFLD agent. Further research is warranted to reveal the mechanisms of auranofin in NAFLD and develop the potential for clinical translation.